Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.66 |
| ▸ | DAO | P14920 | 7/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | LIG1 | P18858 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22071237 | 0.82 | DAO (0.52) | HDAC8DAOPKMLIG1MEN1 | |
| SCHEMBL22711381 | 0.81 | HDAC8 (0.63) | HDAC8DAORAB9AKEAP1NFE2L2 | |
| SCHEMBL5162659 | 0.80 | DAO (0.50) | HDAC8DAOPKMLIG1MEN1 | |
| SCHEMBL3960184 | 0.78 | DAO (0.48) | HDAC8DAOPKMLIG1MEN1 | |
| SCHEMBL16056864 | 0.76 | DAO (0.42) | HDAC8DAOPKMLIG1MEN1 | |
| SCHEMBL3081817 | 0.76 | HDAC8 (0.58) | HDAC8 | |
| SCHEMBL70493 | 0.75 | DAO (0.67) | DAOPKMLIG1MEN1POLB | |
| SCHEMBL19987844 | 0.73 | DAO (0.64) | DAOPKMLIG1MEN1POLB | |
| Hydrochloric Acid SCHEMBL3074364 | 0.73 | DAO (0.64) | DAOPKMLIG1MEN1POLB | |
| SCHEMBL11598753 | 0.73 | DAO (0.64) | DAOPKMLIG1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312348-B2 | RET inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2025-05-27 | — | — | US | disclosed |
| CN-111285874-B | RET inhibitor, pharmaceutical composition thereof and application thereof | 广东东阳光药业股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20220119382-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| EP-3891148-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| US-10752615-B2 | Spirocyclic containing compounds and pharmaceutical uses thereof | GB005, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| CN-111285874-A | RET inhibitors, pharmaceutical compositions thereof and uses thereof | 广东东阳光药业有限公司 | 2020-06-16 | — | — | CN | disclosed |
| WO-2020114494-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-06-11 | — | — | WO | disclosed |
| US-20190263790-A1 | SPIROCYCLIC CONTAINING COMPOUNDS AND PHARMACEUTICAL USES THEREOF | GB005, INC. | 2019-08-29 | — | — | US | disclosed |
| US-9676781-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20150252050-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-09-10 | — | — | US | disclosed |
| CN-101490036-A | Factor XA inhibitors | MILLENNIUM PHARM INC (US) | 2009-07-22 | — | — | CN | disclosed |
| US-7563786-B2 | Substituted thiophenecarboxamides, their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-21 | — | — | US | disclosed |
| US-20090030045-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| EP-2016072-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-01-21 | — | — | EP | disclosed |
| CN-101213195-A | Substituted glycinamides having an antithrombotic and factor xa-inhibiting effect | BOEHRINGER INGELHEIM INT (DE) | 2008-07-02 | — | — | CN | disclosed |
| WO-2007131179-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259924-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20060069082-A1 | Novel substituted thiophenecarboxamides, their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-30 | — | — | US | disclosed |
| EP-0970036-A1 | ARYL- AND HETEROARYLCYCLOHEXENYL SUBSTITUTED ALKENES HAVING RETINOID AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY | Allergan Sales, Inc. (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998039284-A1 | ARYL- AND HETEROARYLCYCLOHEXENYL SUBSTITUTED ALKENES HAVING RETINOID AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY | ALLERGAN SALES, INC. (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030045-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | HDAC8 1117/4885DAO 628/4885PKM 1646/4885 |
| US-20220119382-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | RET, SLC10A2, REL | HDAC8 1506/4885DAO 1574/4885PKM 1762/4885 |
| US-10752615-B2 | Spirocyclic containing compounds and pharmaceutical uses thereof | TEC, ITK, TXK | HDAC8 884/4885DAO 2649/4885PKM 329/4885 |
| US-20060069082-A1 | Novel substituted thiophenecarboxamides, their preparation and their use as medicaments | P2RY11, P2RX5, TPMT | HDAC8 1700/4885DAO 990/4885PKM 1474/4885 |
| US-20070259924-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | HDAC8 1117/4885DAO 628/4885PKM 1646/4885 |
| US-12312348-B2 | RET inhibitors, pharmaceutical compositions and uses thereof | RET, SLC10A2, REL | HDAC8 1506/4885DAO 1574/4885PKM 1762/4885 |
| US-20190263790-A1 | SPIROCYCLIC CONTAINING COMPOUNDS AND PHARMACEUTICAL USES THEREOF | TEC, ITK, TXK | HDAC8 884/4885DAO 2649/4885PKM 329/4885 |
| US-20150252050-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | PGM2, MGAM, GRM1 | HDAC8 3958/4885DAO 126/4885PKM 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.